EGFR and lung carcinoma: Although the traditional therapeutic strategies have been tremendously improved and targeted therapies, such as tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) [4] and immune checkpoint inhibitors, have been successfully used in clinical practice [5], the five-year overall survival rate of lung cancer of all stages combined remains as low as 15.9% [6].